Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy
This clinical trial is testing two treatments for advanced ovarian cancer. One treatment uses two drugs: **T-DXd** (Trastuzumab Deruxtecan) and **bevacizumab**, while the other uses only bevacizumab. The trial is for patients with a type of cancer that shows **HER2** (a protein) on the cancer cells. First, a small group will test the safety of using both drugs together. To join, you must be at least 18, have certain types of ovarian cancer, and have had some chemotherapy already. You cannot join if you have other types of ovarian cancer, certain genetic changes, or recent heart problems. Key Points:
This clinical trial is testing two treatments for advanced ovarian cancer. One treatment uses two drugs: **T-DXd** (Trastuzumab Deruxtecan) and **bevacizumab**, while the other uses only bevacizumab. The trial is for patients with a type of cancer that shows **HER2** (a protein) on the cancer cells. First, a small group will test the safety of using both drugs together. To join, you must be at least 18, have certain types of ovarian cancer, and have had some chemotherapy already. You cannot join if you have other types of ovarian cancer, certain genetic changes, or recent heart problems. Key Points:
- The study involves a safety test first, then a larger trial.
- Participants must have certain types of ovarian cancer and be 18 years or older.
- You cannot join if you have recent heart issues or certain genetic conditions.
How understandable was the trial content above?
Hard to understand
Easy to understand